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Abstract
Background: Angiotensin and serotonin have been identified as inducers of cardiac hypertrophy. DNA 
polymorphisms at the genes encoding components of the angiotensin and serotonin systems have been associated 
with the risk of developing cardiovascular diseases, including left ventricular hypertrophy (LVH).
Methods: We genotyped five polymorphisms of the AGT, ACE, AT1R, 5-HT2A, and 5-HTT genes in 245 patients with 
Hypertrophic Cardiomyopathy (HCM; 205 without an identified sarcomeric gene mutation), in 145 patients with LVH 
secondary to hypertension, and 300 healthy controls.
Results: We found a significantly higher frequency of AT1R 1166 C carriers (CC+AC) among the HCM patients without 
sarcomeric mutations compared to controls (p = 0.015; OR = 1.56; 95%CI = 1.09-2.23). The AT1R 1166 C was also more 
frequent among patients who had at least one affected relative, compared to sporadic cases. This allele was also 
associated with higher left ventricular wall thickness in both, HCM patients with and without sarcomeric mutations.
Conclusions: The 1166 C AT1R allele could be a risk factor for cardiac hypertrophy in patients without sarcomeric 
mutations. Other variants at the AGT, ACE, 5-HT2A and 5-HTT did not contribute to the risk of cardiac hypertrophy.
Introduction
Left-ventricular hypertophy (LVH) is a physiological
adaptation of the heart to increased workload. LVH is fre-
quently secondary to clinical conditions such as hyper-
tension, valvular disease, and myocardial infarction [1,2].
However, some patients develop the cardiac hypertrophy
in the absence of these conditions that impose overwork
to the heart. This primary/essential form of LVH is fre-
quently familial and caused by mutations in sarcomeric
genes, and is designated as hypertrophic cardiomyopathy
(HCM) [3]. Some patients with HCM lack a family his-
tory of the disease, and are thus regarded as sporadic
cases. Several gene polymorphisms have been associated
with the risk of developing LVH, and could also modify
the clinical phenotype in HCM patients [4-6]. Neurohu-
moral factors such as angiotensin II (Ang) and serotonin
(5-hydroxytriptamine; 5-HT) have been identified as
inducers of cardiac hypertrophy [7,8]. These molecules
bind to G protein-coupled receptors on cardiac fibro-
blasts, and stimulate the production and release of
growth factors and cytokines that would induce cardio-
myocyte hypertrophy [9,10]. The interactions between
the angiotensin and serotonin systems in cardiac cells
could play a major role in the development of cardiac
hypertrophy [8].
Serotonin is a molecule produced by several cell types,
such as serotonergic neurons and renal proximal tubular
cells. A large amount of serotonin is stored in blood plate-
lets, bounded to the serotonin transporter (5-HTT). This
serotonin is released during platelet activation and binds
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to specific receptors on target cells stimulating a wide
array of physiological changes, such as platelet aggrega-
tion, vascular contraction, and hyperplasia of the smooth
muscle cells [11,12]. In the heart, serotonin stimulates
sympathetic afferent nerves and causes contraction of the
coronaries during ischemia. Studies with mice genetically
modified for 5-HT receptors implicated the serotonin
pathway in ventricular hypertrophy [13,14]. This pro-
hypertrophic effect would require the uptake of serotonin
into cardiomyocytes, and could be partly mediated by a
mitochondrial dysfunction [14]. Polymorphisms in the 5-
HT2A receptor gene have been linked to receptor func-
tion [15]. A 5-HTT gene polymorphism located in the
promoter region has been associated with gene expres-
sion and an increased uptake of 5-HT in platelets [16].
Due to the central role of serotonin in brain function
these gene variants have been extensively studied in neu-
rological and psychiatric traits, but little is known about
their role in cardiac hypertrophy [17].
Angiotensin II is formed from angiotensin I by the
action of the angiotensin-II converting enzyme (ACE).
Ang is a potent vasoconstrictor, but also modulates car-
diac hypertrophy [18]. The pharmacological blockade of
ACE reduced the hypertrophy secondary to myocardial
infarction and hypertension [19]. Polymorphisms in the
genes encoding angiotensinogen (AGT), angiotensin-II
converting enzyme (ACE), and angiotensin II type 1
receptor (AT1R) have been extensively studied in cardio-
vascular diseases, including LVH [4,20,21]. The ACE
insertion/deletion (I/D) variant was related with the
e x t e n t  o f  H C M  i n  p a t i e n t s  with sarcomeric mutations
[22,23]. A common single nucleotide polymorphism
(SNP) in the 3' untranslated region (UTR) of AT1R (1166
A/C) was associated with hypertension and coronary
artery stenosis and vasoconstriction [24-26]. This SNP
could also modulate the phenotype in patients with HCM
[27].
Considering the role of the serotonin and angiotensin
systems in cardiac hypertrophy, we hypothesized that
DNA variants in the 5-HT2A,  5-HTT,  AGT,  ACE, and
AT1R genes could influence the risk for LVH. To investi-
gate this association, we genotyped patients with LVH
and healthy controls for DNA polymorphisms at these
genes. We also determined the effect of these gene poly-
morphisms on onset age and the extent of the hypertro-
phy.
Methods
Patients and controls
This study was part of a research project designated to
analyse the association of DNA-variants to HCM-risk. In
the period 1999-2009, a total of 245 non-related patients
were recruited through the Cardiology Departments of
Hospital Universitario Central Asturias (HUCA) and
Hospital Universitario Valdecilla-Santander. The exis-
tence of cardiac hypertrophy was suspected on the basis
of clinical manifestations (exertional dyspnea, palpita-
tions, angina, or syncope). In all the patients, we used
two-dimensional echocardiography to determine the
interventricular septal thickness (IVS) by measuring in
diastole at the level of the left ventricle minor axis [28].
The posterior wall thickness (PWT) was also measured,
and the left ventricular wall thickness (LVWT) calculated
as the sum of IVS and PWT.
Table 1 summarizes the main characteristics of
patients. All them fulfilled the next inclusion criteria:
they had an interventricular septum (IVS) > 13 mm, and
the hypertrophy was not secondary to other cardiac dis-
eases capable of producing LVH (such as hypertension,
valvular disease, and myocardial infarction). Patients with
relatives who had also been diagnosed with HCM and/or
sudden cardiac death (SCD) were classified as familial
cases. In apparently sporadic cases, we performed electro
and echocardiographic examination to their parents
when they were available for the study.
A second group of patients was composed by 145 non-
related hypertensives with LVH (59% male; mean age at
diagnosis, 58 ± 17 years; mean IVS = 15 ± 5 mm). The
controls were a total of 300 healthy individuals aged 20 to
75 years (mean age 51 ± 17; 54% male), recruited through
the Blood Bank and the Cardiology Department of
HUCA. They did not have symptoms of cardiovascular
diseases, but none was echocardiographically evaluated
to exclude the presence of asymptomatic LVH. A total of
150 of these controls were examined through electrocar-
diography to exclude the existence of cardiac diseases. All
the patients and controls were Caucasians from the
Northern Spain regions of Asturias and Cantabria, and
gave their informed consent to participate in the study,
approved by the Ethical Committee of Hospital Central
Asturias.
Sarcomeric gene mutations
Because HCM is commonly linked to mutations in car-
diac sarcomeric genes, we determined the presence of
mutations in the most frequently mutated genes in the
245 HCM-patients. The beta-myosin heavy chain
(MYH7), cardiac troponin T (TNNT2), alpha-tropomyo-
sin (TPM1), cardiac troponin I (TNNI3), and myosin
binding protein C3 (MYBPC3) genes were sequenced as
reported [29,30].
Genotyping of the serotonin and angiotensin system 
polymorphisms
Two types of polymorphisms were analysed: insertion/
deletion (ACE and 5-HTT), and SNPs (AGT, AT1R, and 5-
HT2A). The genomic DNA of patients and controls was
polymerase chain reaction (PCR) amplified (32 cycles)Coto et al. Journal of Translational Medicine 2010, 8:64
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Page 3 of 9
Table 1: Main characteristics of the patients with HCM and hypertensive LVH
Total HCM
(n = 245)
Familial HCM
(n = 105; 43%)
Sporadic HCM*
(n = 140; 57%)
Hypertensive LVH
(n = 145)
Mean age at
Diagnosis (years)
46 ± 13 37 ± 18 43 ± 19 58 ± 17
Range 8-76 8-72 21-76 35-75
Male 144 (59%) 68 (65%) 76 (56%) (59%)
Mean BMI
Male 27 ± 3 26 ± 3 27 ± 4 28 ± 4
Female 26 ± 4 25 ± 3 26 ± 3 28 ± 5
Mean IVS# 20 ± 5 22 ± 6 18 ± 7 15 ± 5
Mean PWT# 13 ± 5 14 ± 5 11 ± 6 10 ± 6
Mean LVWT# 34 ± 6 36 ± 6 30 ± 6 26 ± 6
Dyspnea 168 (69%) 78 (74%) 90 (64%) 30%
NYHA index#
Class I-II 120 (49%) 49 (47%) 71 (51%) 85%
Class III-IV 48 (20%) 29 (28%) 19 (14%) 15%
Angina 96 (39%) 53 (50%) 43 (31%) 16%
Syncope 48 (20%) 25 (24%) 23 (16%) 6%
Atrial fibrillation 47 (19%) 23 (22%) 24 (17%) 15%
Arrhythmia (Holter 
monitoring)
55 (22%) 21 (20%) 34 (24%) 18%
LVOT > 30 mm Hg# 72 (29%) 34 (32%) 38 (27%) 30%
Sarcomeric mutations 40 (16%) 30 (29%) 10 (7%) ND
MYH7 12 (5%) 11 (10%) 1(< 1%)
MYBPC3 23 (9%) 16 (15%) 7(5%)
TNNT2 4 (2%) 2 (2%) 2 (1%)
TPM1 1 (< 1%) 1 (1%) 0
* In 45 patients none of the parents were studied to exclude the presence of asymptomatic LVH.
# IVS: interventricular septum; PWT: posterior wall thickness; LVWT: left ventricular wall thickness; NYHA: New York Heart Association 
functional class; LVOT: left ventricular outflow tract gradient.
The presence of sarcomeric mutations was not determined (ND) in the hypertensive-LVH patients.Coto et al. Journal of Translational Medicine 2010, 8:64
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with specific primers, and the reactions were directly
electrophoresed on 3% agarose gels (insertion/deletion
alleles) or after digestion with a restriction enzyme
(SNPs), as reported [31-33]. Alleles in the coding region
were numbered following the standard nomenclature
[34]. The reference numbers for the five polymorphisms
were: rs699 (AGT, c.803 T/C); rs6313 (5-HT2A, c.102 T/
C); rs5186 (AT1R, c.1166 A/C); rs4646994 (ACE, intron
16 I/D); rs4795541 (5-HTT, promoter l/s) (see the
Ensembl database for the definition of these gene vari-
ants; http://www.ensembl.org). In the additional table 1
we summarized the primer sequences and genotyping
conditions for the five polymorphisms.
Statistical analysis
The Kolmogorov-Smirnov was used to determine
whether the continuous variables followed a normal dis-
tribution. The mean values for variables that were nor-
mally distributed were compared between the different
groups through the ANOVA. Allele and genotype fre-
quencies between patients and controls were compared
through a χ2 test. Odds ratios (ORs) and their 95% confi-
dence intervals (CIs) were also calculated. The SPSS
package (v. 11.0) was used for all the statistical analysis. A
p < 0.05 was considered statistically significant. Power
calculation at p = 0.05 and p = 0.01 was performed for all
the significant genetic associations with an online pro-
gram http://statpages.org/proppowr.html.
Results
Table 1 summarizes the main characteristics of the
patients. A total of 75 of the HCM patients had at least
one relative who was also affected by HCM or had suf-
fered SCD. The remaining 170 patients did not have a
family history of the disease, but the existence of asymp-
tomatic relatives with HCM could not be excluded. In 90
of these patients we performed electro and echocardio-
graphic examination to both parents, and to only one par-
ent in 35 cases. HCM was also found in the father or the
mother of 30 of these 125 HCM-patients, that could thus
be regarded as familial cases. In 45 patients, none of the
parents were available for study.
A total of 40 of the 245 HCM-patients had a mutation
in the MYH7, MYBPC3, TPM1, TNNI3, or TNNT2 genes
(Additional table 2). Sarcomeric mutations were more
frequent in patients with familial HCM compared to
apparently sporadic cases (30% vs. 7%). The genotyping
of the 5-HT2A, 5-HTT, AGT, ACE, and AT1R polymor-
phisms showed a significantly higher frequency of carri-
ers of the AT1R C allele (AC+CC genotypes) in the HCM
patients without sarcomeric gene mutations compared to
the healthy controls (p = 0.015; OR = 1.56; 95% CI = 1.09-
2.23) (Table 2). The difference was no significant when
the Bonferroni's correction was applied p < 0.01). The
sample size (205 patients and 300 controls) was enough
to reach a power of 75% at a p = 0.05 (for a power of 80%,
a total of 225 patients and 338 controls should be
required at a p = 0.05, and 336 patients and 504 controls
at a p = 0.01). The frequency of AT1R C-carriers did not
differ between hypertensives with LVH and controls (50%
vs. 47%).
We examined the difference for the main characteris-
tics between the 5-HT2A, 5-HTT, AGT, ACE, and AT1R
genotypes in the 205 patients without sarcomeric muta-
tions. We found a higher frequency of familial cases
among AT1R C-carriers (p = 0.02), and this could reflect a
predisposition to develop familial cardiac hypertrophy
linked to these genes. We also found a higher mean IVS
and LVWT among patients who were AT1R CC/AC com-
pared to AA in both HCM groups, with and without sar-
comeric mutations (Table 3). The AT1R genotype did not
modify the mean IVS and LVWT among the hypertensive
patients.
Several DNA polymorphisms in the angiotensin system
genes have been proposed as modifiers of the phenotype
in families with sarcomeric mutations. In our study,
patients with a sarcomere mutation (n = 40) who were
AT1R  CC/AC had higher mean IVS and LVWT, and
lower mean onset age compared to AT1R  AA. In addi-
tion, AT1R C - carriers had a higher frequency of familial
cases (table 3). However, these differences did not reach
statistical significance, probably because they were based
on only 40 index patients with a sarcomeric mutation.
Because  MYH7  mutations have been associated with
more severe forms of HCM compared to MYBPC3, we
also compared the effect of the AT1R  SNP according to
the mutated gene. We studied 19 mutation carriers from
the 12 families with a MYH7-mutation, and 64 mutation
carriers from the 23 families with a MYBPC3-mutation
(Additional table 2). We found a total of 48 AT1R C carri-
ers, 9 in the MYH7 and 39 in the MYBPC3 groups, and
the mean LVWT was higher among these AT1R C carri-
ers compared to AT1R  AA in the two groups, although
the difference did not reach statistical significance (p =
0.053).
Discussion
In this study we genotyped 245 HCM-patients and 300
healthy controls for 5 polymorphisms in five candidate
genes of the angiotensin and serotonin systems. We iden-
tified an HCM-causative mutation in one of the five most
commonly mutated sarcomeric genes (MYH7, MYBPC3,
TPM1, TNNI3, or TNNT2) in 40 cases, but we cannot
exclude that other patients harbour mutations in any of
the other genes that have been linked to HCM. However,
we think this would affect a reduced number of cases
because the five sarcomeric genes represent > 90% of the
mutations found in HCM-patients (see the cardiogenom-Coto et al. Journal of Translational Medicine 2010, 8:64
http://www.translational-medicine.com/content/8/1/64
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Table 2: Genotype and allele frequencies for the five polymorphisms in patients and healthy controls
Polymorphism HCM* N=205 Hypertensive LVH N = 145  Controls
 N = 300
5-HT2A (c.102 T/C)
Rs6313
TT 45 (22%) 24 (17%) 60 (20%)
TC 105 (51%) 79 (54%) 149 (50%
CC 55 (27%) 42 (29%) 91 (30%)
T 0.47 0.43 0.45
C 0.53 0.57 0.55
5-HTT (l/s)
Rs4795541
ll 72 (35%) 48 (33%) 91 (30%)
ls 102 (50%) 71 (49%) 147 (49%)
ss 31 (15%) 26 (18%) 62 (21%)
l 0.60 0.58 0.55
s 0.40 0.42 0.45
ACE (I/D)
Rs4646994
DD 72 (35%) 54 (37%) 119 (40%)
ID 100 (48%) 68 (45%) 135 (45%)
II 35 (17%) 23 (15%) 46 (15%)
D 0.59 0.61 0.62
I 0.41 0.39 0.38Coto et al. Journal of Translational Medicine 2010, 8:64
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ics database; http://www.cardiogenomics.org). The fre-
quency of patients with a sarcomeric mutation (16.3%)
was lower than the frequency previously reported in our
population (27%). This could be partly attributed to a
lower frequency of cases with affected relatives and a
mean higher onset age for the patients in this study, com-
pared to previous reports [29,30].
We found a significantly higher frequency of AT1R C-
carriers among patients negative for sarcomeric muta-
tions, compared to healthy controls. This could represent
a predisposition to develop HCM among individuals with
this AT1R allele, although the OR was relatively low (1.56)
in this group of patients and 41% of the 205 patients with-
out a myofilament mutation were non-carriers of this
allele. The AT1R 1166 C has been associated with the risk
for several cardiovascular traits, including hypertension,
coronary artery vasoconstriction, and coronary artery
disease. Some authors did not find a significant associa-
tion between this allele and the risk for HCM [35]. How-
ever, in these studies the patients were not selected by the
presence/absence of sarcomeric gene mutations, and this
could result in a non-significant association if patients
with a causative HCM mutation were included in the
study. In fact, the AT1R  frequencies did not differ
between our patients with sarcomeric mutations and
controls. Moreover, if we compared the AT1R  genotype
frequencies between all the HCM patients (n = 245) and
the controls (n = 300), no significant difference was found
for 1166 C carriers (p = 0.06). A total of 30 patients with-
out sarcomeric mutations had a positive family history of
HCM. It is possible that the frequency of AT1R C carriers
was also significantly higher among these affected rela-
tives. However, this information was not available
because these individuals were not genotyped for the
AT1R polymorphism.
The AT1R SNP has also been proposed as a modifier of
the clinical phenotype in HCM [4-6]. In their analysis of
389 HCM-patients (45% with a family history of HCM
AGT (c.803 T/C)
Rs699
MM 64 (31%) 54 (37%) 95 (32%)
MT 100 (49%) 68 (48%) 145 (48%)
TT 41 (19%) 22 (15%) 60 (20%)
M 0.55 0.61 0.56
T 0.45 0.39 0.44
AT1R (c.1166 A/C)#
Rs5182
AA 84 (41%) 72 (50%) 156 (53%)
AC 94 (46%) 60 (41%) 114 (37%)
CC 27 (13%) 13 (9%) 30 (10%)
A 0.64 0.70 0.71
C 0.36 0.30 0.29
*Patients without sarcomeric mutations.
# HCM vs. controls: p = 0.015; OR = 1.56 (95%CI = 1.09-2.23); AC + CC HCM patients vs. controls.
Table 2: Genotype and allele frequencies for the five polymorphisms in patients and healthy controls (Continued)Coto et al. Journal of Translational Medicine 2010, 8:64
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and/or SCD), Perkins et al. reported a lower mean age at
diagnosis among AT1R CC compared to AT1R AA (37.9
vs. 43.2 years, respectively). We did not find significantly
different mean onset ages between the AT1R genotypes,
although patients with a sarcomeric mutation and AT1R
C-carriers had a lower mean onset age. This suggested
that the AT1R genotype could be a modifier of the onset
age among patients with a causative sarcomeric mutation.
Perkins et al. also reported higher mean left ventricular
wall thickness and a higher frequency of severe hypertro-
phy (> 30 mm) among AT1R CC patients. This associa-
tion with the extent of LVH was also reported by others
[27]. We also found a higher mean LVWT among AT1R
C-carriers in both, patients with and without sarcomeric
mutation. Moreover, this allele was associated with
higher LVWT in patients with MYH7  and  MYBPC3
mutations. This suggested that the AT1R genotype could
be a modifier of the extent of the hypertrophy in our pop-
ulation, in patients with and without sarcomeric muta-
tions. The role of the AT1R  SNP as a modifier of the
phenotype was also supported by the finding of a higher
frequency of familial HCM among patients with sarco-
meric mutations and 1166 C-carriers. This could be the
consequence of a more severe phenotype among AT1R C-
carriers, resulting in a higher penetrance of the sarco-
meric mutation among carriers of this AT1R allele. How-
ever, our definition of familial HCM was incomplete
because in 19% of our patients who did not have a family
history of the disease we could not exclude the presence
of asymptomatic LVH in their parents. It is thus possible
that the frequency of familial cases was higher than esti-
mated in our patients, and this could affect the results.
The  AT1R  1166A/C (SNP rs5186) is in the 3' UTR
region, in a sequence that binds microRNA (miRNA) -
155. MiRNAs are small (approximately 22 nucleotides
long) non-coding RNAs that bind to sequences in the 3'
UTRs of mRNAs by complementary base-pairing, and
repress mRNA post-transcriptionally. The + 1166 C-allele
determines the interruption of the base-pairing comple-
mentarity with miR-155, and this resulted in the
increased translation of AT1R  compared to the mRNA
containing 1166 A [36]. Both, AT1R  and miR-155, are
abundantly expressed in the same cell types (e.g. VSMCs
and endothelial). The regulation of AT1R by miR-155 and
the differential binding of this miRNA to mRNAs with
1166 A or C provided a mechanism by which this SNP
could lead to a heterogeneous AT1R expression and car-
diovascular risk. Although a direct effect of this SNP on
Table 3: Mean (± Standard deviation) interventricular septum, posterior wall thickness, left ventricular wall thickness, age 
at the diagnostis and body mass index values, and frequency of cases with affected relatives, according to the AT1R 
genotype in the 205 HCM-patients without sarcomeric mutations, the 40 patients with a sarcomeric mutation, and the 145 
patients with hypertensive LVH
IVS
(mm)
PWT
(mm)
LVWT
(mm)
Age (years) BMI Familial
HCM#
HCM-No
mutation1
CC (n = 27) 21 ± 4 13 ± 3 34 ± 5 49 ± 18 26 ± 5 10 (37%)
AC (n = 94) 21 ± 5 13 ± 4 33 ± 4 46 ± 18 27 ± 4 40 (43%)
AA (n = 84) 19 ± 5 13 ± 4 32 ± 4 48 ± 16 27 ± 5 25 (30%)
HCM-Mutation2
CC (n = 5) 23 ± 4 16 ± 3 39 ± 4 38 ± 4 21 ± 4 4 (80%)
AC (n = 14) 22 ± 5 14 ± 5 35 ± 5 36 ± 5 21 ± 5 12 (86%)
AA (n = 21) 18 ± 5 14 ± 4 31 ± 5 45 ± 5 20 ± 5 14 (67%)
Hypertensive
-LVH
CC (n = 13) 16 ± 4 10 ± 5 25 ± 5 60 ± 8 28 ± 2 ND
AC (n = 60) 16 ± 3 9 ± 4 25 ± 4 58 ± 7 27 ± 2 ND
AA (n = 72) 15 ± 2 10 ± 5 24 ± 4 59 ± 9 28 ± 3 ND
# We did not determine (ND) the existence of a family history of LVH in the hypertensive-LVH group.
1 P = 0.016, IVS CC + AC vs. AA.
2 P = 0.017, IVS CC + AC vs. AA.Coto et al. Journal of Translational Medicine 2010, 8:64
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AT1R expression could explain its association to cardiac
hypertrophy and other cardiovascular disorders, we can-
not exclude that this association was a consequence to its
linkage disequilibrium with other AT1R variants. For this
gene two main haplotype blocks have been identified, one
defined by markers in the promoter region and the other
by SNPs rs5182 and rs5186 in the 3' region [37,38]. A
resequencing of the AT1R in patients carrying the C-
allele should be necessary to identify other variants that
could be linked to the risk for cardiac hypertrophy. In
addition, the pharmacological blockade of angiotensin II
receptors has been shown to reduce LVH, and could be
useful to treat this disease [39]. A significant association
between the AT1R 1166 A/C SNP and LVH change dur-
ing antihypertensive treatment with AT1R antagonists
has been reported [40]. In this context, it should be inter-
esting to evaluate the effect of the AT1R genotypes on the
response to AT1R antagonists in patients with HCM.
Finally, our study has some limitations that could affect
the results. The association between the AT1R SNP and
HCM was significant (p = 0.015), but the OR for allele C-
carriers was 1.56 and the lower limit of CI (1.09) was
close to 1. Although the association was plausible consid-
ering the statistical power, it should be replicated in
larger cohorts and from different populations. As dis-
cussed above, the five sarcomeric genes analysed in our
patients would represent > 90% of the mutated genes in
HCM patients. However, mutations in more than 12
genes have been found in HCM cases and some of the
205 patients could be included as carriers of a myofila-
ment mutation if all these genes were studied. Third, we
found a significant association between the AT1R  and
familial HCM in patients without sarcomeric gene muta-
tions, but our classification of familial/sporadic cases was
incomplete because we did not perform ECG or echocar-
diographic examination to all the first degree relatives of
our patients. It is thus possible that some patients had rel-
atives with asymptomatic LVH, and could thus be classi-
fied as familial cases.
Conclusions
The AT1R 1166 A/C polymorphism was associated with
HCM in patients without sarcomeric gene mutations. In
addition, the frequency of familial hypertrophy was
higher among carriers of this allele, and we also found a
trend toward higher left ventricular thickness among
these 1166 C-carries. Our work suggested that the AT1R
gene variation could contribute to the risk of developing
cardiac hypertrophy, being also a modifier of the pheno-
type.
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